XBiotech Inc.
XBITHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, XBiotech Inc. focuses on Biotechnology services and products. XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. Valued at $58.8M, XBIT is a micro-cap name in its sector. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Market Cap
$58.8M
Beta
0.80
P/E (TTM)
—
P/E (Fwd)
14.85
EPS (TTM)
$-1.48
EPS (Fwd)
$0.13
ROE
-29.9%
ROA
-19.3%
Cash
$109.5M
Total Debt
$0
Free CF
-$28.5M
52W Change
-24.9%
Annual Financials
Cash vs Debt
Where XBIT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, XBIT finished 13.79% below its 150-day moving average ($2.32) and 14.89% below its 200-day moving average ($2.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XBIT overbought or oversold?
At the October 20, 2026 close, XBIT's RSI(14) was 31.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
XBiotech Inc. reports $109.5M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$28.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -29.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $4.0M (2022) to $0 (2025), a 100% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for XBiotech Inc. and its sector.